Chinese maker of surgical robotic systems for minimally invasive laparoscopic and endoscopic surgery.
Chinese maker of surgical robotic systems for minimally invasive laparoscopic and endoscopic surgery.
In one line: China's answer to a smaller Intuitive Surgical.
Moat: narrow (IP / patents, regulatory licence, switching costs). Regulatory approvals and surgeon training/installed base create switching costs once a hospital adopts a robotic platform.
Headquarters: Shenzhen, China · Employees: 602
Size Shenzhen Edge Medical (2675.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $1.21B, the 530th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$24.60 on 18 Nov 2026.
Performance Over six months the shares fell 50.9%, against -9.9% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 2nd lowest of 20 in its peer set.
Growth Revenue grew 132.2% over the last twelve months (peer median +12.0%); the operating margin is 2.0% (peer median 16.0%).
Valuation It trades at 120.2× forward earnings against a peer median of 28.2× (most expensive of 15).
Capital Return on invested capital runs 6.2 points below its cost of capital (8.2% WACC).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | HK$699M | HK$494M | HK$173M | HK$53.1M | HK$0 |
| Revenue growth | — | +185% | +227% | — | — |
| Gross profit | HK$457M | HK$318M | HK$93.7M | HK$18.2M | -HK$8.00M |
| EBITDA | HK$37.0M | -HK$61.3M | -HK$282M | -HK$277M | -HK$327M |
| Net income | -HK$21.4M | -HK$96.1M | -HK$237M | -HK$235M | -HK$290M |
| Free cash flow | -HK$244M | -HK$213M | -HK$270M | -HK$420M | -HK$142M |
| Capital expenditure | HK$16.6M | HK$3.88M | HK$29.3M | HK$70.3M | HK$9.01M |
| Total debt | n/a | HK$11.0M | HK$19.2M | HK$29.4M | HK$18.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shenzhen Edge Medical 2675.HK | $1.21B | -51% | +132% | 2% | 120.2× | n/a |
| Intuitive Surgical ISRG | $146B | -6% | +20% | 32% | 34.8× | 29.6% |
| Shanghai MicroPort MedBot (Group) 2252.HK | n/a | -26% | n/a | n/a | n/a | n/a |
| Medtronic MDT | $129B | +30% | +10% | 20% | 16.8× | 9.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2675.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -23.1% | -5.8% | 5th lowest of 21 |
| 6-month return | -50.9% | -9.9% | 2nd lowest of 20 |
| Distance from 52-week high | -66.6% | -37.5% | 3rd lowest of 21 |
| Revenue growth (TTM) | +132.2% | +12.0% | highest of 19 |
| Operating margin | 2.0% | 16.0% | 7th lowest of 20 |
| Forward P/E | 120.2× | 28.2× | most expensive of 15 |
| ROIC minus cost of capital | -6.2 pp | +0.2 pp | 6th lowest of 20 |
| Net debt / EBITDA | -56.7× | -1.0× | least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shenzhen Edge Medical 2675.HK | Hong Kong | $1.21B | -51% | +132% | 2% | 120.2× | n/a | n/a |
| Eyebright Medical Technology (Beijing) 688050.SS | China | $1.21B | -16% | +21% | 16% | 23.9× | 10.3% | +40.3% |
| Tandem Diabetes Care TNDM | United States | $1.19B | +13% | +7% | -2% | n/a | n/a | n/a |
| Sansure Biotech 688289.SS | China | $1.24B | -17% | -1% | 1% | 35.6× | n/a | n/a |
| NovoCure NVCR | United States | $1.25B | -40% | +13% | -17% | n/a | n/a | n/a |
| STAAR Surgical STAA | United States | $1.27B | -23% | +42% | 7% | 46.9× | 35.1% | +7.9% |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.14B | -29% | -6% | 18% | 24.9× | 11.3% | -3.5% |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | -4% | -4% | 36% | 18.2× | 1.7% | +9.9% |
| Sonoscape Medical 300633.SZ | China | $1.31B | -10% | +18% | 4% | 34.7× | n/a | n/a |
| Suzhou Sepax Technologies 688758.SS | China | $1.31B | +8% | +28% | 40% | 46.0× | 22.8% | +23.6% |
| Beijing Balance Medical Technology 688198.SS | China | $1.31B | -32% | +10% | 28% | 41.5× | 20.7% | +27.6% |
| Alpha Tau Medical DRTS | United States | $1.11B | +7% | n/a | n/a | n/a | n/a | n/a |
| Ovctek China 300595.SZ | China | $1.33B | -25% | 0% | 28% | 19.4× | 8.3% | +16.5% |
| Alphatec ATEC | United States | $1.10B | -14% | +15% | -3% | 15.1× | n/a | n/a |
| Freenome FRNM | United States | $1.08B | n/a | n/a | 36% | n/a | n/a | n/a |
| CLASSYS 214150.KS | South Korea | $1.08B | -60% | +16% | 43% | 13.7× | -9.2% | +34.5% |
| Integra LifeSciences IART | United States | $1.08B | -10% | +1% | 12% | 6.0× | 5.9% | +3.6% |
| Mingyue Optical Lens 301101.SZ | China | $1.07B | -4% | +14% | 25% | 31.6× | 8.8% | +8.8% |
| Guangzhou Hexin Instrument 688622.SS | China | $1.06B | +21% | -29% | -74% | n/a | n/a | n/a |
| SI-BONE SIBN | United States | $1.06B | +59% | +14% | -8% | n/a | n/a | n/a |
| IRadimed IRMD | United States | $1.05B | -9% | +11% | 32% | 34.3× | 18.5% | +21.5% |